Short peptides, e.g. setmelanotide, are now in various phases of clinical trials for the treatment of patients with severe obesity due to rare genetic disorders in the leptin-melanocortin pathway (14–16). The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.